A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Primary diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is based on detection of virus RNA in nasopharyngeal swab samples. In addition, analysis of humoral immunity against SARS-CoV-2 has an important role in viral diagnostics and seroprevalence estimates.
METHODS: We developed and optimized an enzyme immunoassays (EIA) using SARS-CoV-2 nucleoprotein (N), S1 and receptor binding domain (RBD) of the viral spike protein, and N proteins from SARS, Middle East respiratory syndrome (MERS), and 4 low-pathogenic human CoVs. Neutralizing antibody activity was compared with SARS-CoV-2 IgG, IgA, and IgM EIA results.
RESULTS: The sensitivity of EIA for detecting immune response in COVID-19 patients (n = 101) was 77% in the acute phase and 100% in the convalescent phase of SARS-CoV-2 infection when N and RBD were used as antigens in IgG and IgA specific EIAs. SARS-CoV-2 infection significantly increased humoral immune responses against the 229E and NL63 N proteins. S1 and RBD-based EIA results had a strong correlation with microneutralization test results.
CONCLUSIONS: The data indicate a combination of SARS-CoV-2 S1 or RBD and N proteins and analysis of IgG and IgA immunoglobulin classes in sera provide an excellent basis for specific and sensitive serological diagnostics of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:224 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 224(2021), 2 vom: 15. Juli, Seite 218-228 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jalkanen, Pinja [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.07.2021 Date Revised 07.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiab222 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324589158 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324589158 | ||
| 003 | DE-627 | ||
| 005 | 20231225190633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiab222 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1081.xml |
| 035 | |a (DE-627)NLM324589158 | ||
| 035 | |a (NLM)33905505 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jalkanen, Pinja |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Primary diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is based on detection of virus RNA in nasopharyngeal swab samples. In addition, analysis of humoral immunity against SARS-CoV-2 has an important role in viral diagnostics and seroprevalence estimates | ||
| 520 | |a METHODS: We developed and optimized an enzyme immunoassays (EIA) using SARS-CoV-2 nucleoprotein (N), S1 and receptor binding domain (RBD) of the viral spike protein, and N proteins from SARS, Middle East respiratory syndrome (MERS), and 4 low-pathogenic human CoVs. Neutralizing antibody activity was compared with SARS-CoV-2 IgG, IgA, and IgM EIA results | ||
| 520 | |a RESULTS: The sensitivity of EIA for detecting immune response in COVID-19 patients (n = 101) was 77% in the acute phase and 100% in the convalescent phase of SARS-CoV-2 infection when N and RBD were used as antigens in IgG and IgA specific EIAs. SARS-CoV-2 infection significantly increased humoral immune responses against the 229E and NL63 N proteins. S1 and RBD-based EIA results had a strong correlation with microneutralization test results | ||
| 520 | |a CONCLUSIONS: The data indicate a combination of SARS-CoV-2 S1 or RBD and N proteins and analysis of IgG and IgA immunoglobulin classes in sera provide an excellent basis for specific and sensitive serological diagnostics of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a coronavirus proteins | |
| 650 | 4 | |a enzyme immunoassay | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a respiratory infection | |
| 650 | 4 | |a serology | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Coronavirus Nucleocapsid Proteins |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Phosphoproteins |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a nucleocapsid phosphoprotein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Pasternack, Arja |e verfasserin |4 aut | |
| 700 | 1 | |a Maljanen, Sari |e verfasserin |4 aut | |
| 700 | 1 | |a Melén, Krister |e verfasserin |4 aut | |
| 700 | 1 | |a Kolehmainen, Pekka |e verfasserin |4 aut | |
| 700 | 1 | |a Huttunen, Moona |e verfasserin |4 aut | |
| 700 | 1 | |a Lundberg, Rickard |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathi, Lav |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Hira |e verfasserin |4 aut | |
| 700 | 1 | |a Ritvos, Mikael A |e verfasserin |4 aut | |
| 700 | 1 | |a Naves, Rauno |e verfasserin |4 aut | |
| 700 | 1 | |a Haveri, Anu |e verfasserin |4 aut | |
| 700 | 1 | |a Österlund, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Kuivanen, Suvi |e verfasserin |4 aut | |
| 700 | 1 | |a Jääskeläinen, Anne J |e verfasserin |4 aut | |
| 700 | 1 | |a Kurkela, Satu |e verfasserin |4 aut | |
| 700 | 1 | |a Lappalainen, Maija |e verfasserin |4 aut | |
| 700 | 1 | |a Rantasärkkä, Kaisa |e verfasserin |4 aut | |
| 700 | 1 | |a Vuorinen, Tytti |e verfasserin |4 aut | |
| 700 | 1 | |a Hytönen, Jukka |e verfasserin |4 aut | |
| 700 | 1 | |a Waris, Matti |e verfasserin |4 aut | |
| 700 | 1 | |a Tauriainen, Sisko |e verfasserin |4 aut | |
| 700 | 1 | |a Ritvos, Olli |e verfasserin |4 aut | |
| 700 | 1 | |a Kakkola, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Julkunen, Ilkka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 224(2021), 2 vom: 15. Juli, Seite 218-228 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:224 |g year:2021 |g number:2 |g day:15 |g month:07 |g pages:218-228 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiab222 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 224 |j 2021 |e 2 |b 15 |c 07 |h 218-228 | ||